Objective: We hypothesized that aerosolized inhaled hypertonic saline given at the onset of resuscitation will decrease acute lung injury following hemorrhagic shock, by inhibiting the release of epithelial derived proinflammatory mediators.
T here has been intensive investigation into the pathophysiology of the acute respiratory distress syndrome (ARDS) since it was first described by Ashbaugh and Petty (1) over 40 yrs ago. It is now understood that a maladaptive immune response is central in the pathogenesis of acute lung injury (ALI) and multiple organ failure (2) . The traditional view of ALI focuses on the interaction between the polymorphonuclear neutrophil (PMN) and injured endothelium; however, hemorrhagic shock also disrupts the bronchial epithelium, leading to lung leak and influx of edematous fluid. Hypertonic saline, at a cellular level, decreases alveolar macrophage activation, PMN recruitment, priming and activation, as well as cell surface adhesion molecule expression (3) . Clinically, inhaled hypertonic saline (HTS) is used to treat inflammation in cystic fibrosis (CF) and neonatal bronchiolitis. The level of interleukin (IL)-8, a chemokine expressed by pulmonary epithelial cells and macrophages, is elevated in CF, and inhibited by HTS in vitro (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Serine proteases (i.e., neutrophil elastase) are thought to be the key mediators; however, recent evidence highlights the increasingly important role of matrix metalloproteinases (MMPs). MMPs have a prominent role in the regulation of lung inflammation. Specifically, MMP-13 is increased in chronic obstructive pulmonary disease, produced by type II pneumocytes. Recent data have implicated MMP-13 in the development of sepsis-mediated ALI, although the role of MMP-13 in ALI following trauma remains unclear (15, 16) .
Given the central role of the pulmonary epithelium in ALI, nebulization has the advantage of achieving high concentrations of the therapy without producing systemic side effects. Consequently, we hypothesize that inhaled HTS modulates the pulmonary epithelial inflammatory response following hemorrhagic shock and inhibits the release of proinflammatory agents. facility with 12-hr light/dark cycles and free access to food and water for a period of at least 1 wk prior to experimental procedures. Pentobarbital sodium was purchased from Abbott Labs (Chicago, IL). Polyethylene tubing was acquired from Fisher Scientific (Pittsburgh, PA), and heparin was purchased from American Pharmaceutical Partner (Schaumburg, IL). Arterial blood gas and serum sodium concentrations were measured by iSTAT (Abbott Point of Care, Princeton, NJ). All other reagents were purchased from Sigma-Aldrich Corp. (St. Louis, MO) unless otherwise specified. Continuous blood pressure measurement was performed using a ProPaq invasive monitoring device (Welch-Allyn, Skaneateles Falls, NY). CL-82198, a selective MMP-13 inhibitor was purchased from EMD (San Diego, CA).
Experimental Model. Anesthesia was given by intraperitoneal injection of 50 mg/kg sodium pentobarbital. Local anesthesia was performed by subcutaneous injection of 1% lidocaine, and heparin (60 units/kg body weight) was added to the shed blood (SB). The femoral artery and vein were cannulated with polyethylene 50 tubing. A separate skin incision was created to tunnel the catheters prior to closure of the groin incision. After a 1-hr observation period, a 3-cm midline laparotomy was performed to mimic tissue injury. To normalize preshock oxygenation, the animal was placed on 40% O 2 using an air-oxygen mixer (Sechrist, Anaheim, CA) at a flow rate of 2 L/min. Shock was induced by removing 40% of the animal's blood volume through an arterial catheter within 10 mins of initiating the controlled hemorrhage. As a result, a mean arterial pressure of 30 mm Hg was achieved, and sustained for 45 mins by withdrawing or returning SB as needed (17) . Body temperature was monitored rectally and euthermia was maintained with a heat lamp. Vital signs were recorded every 10 mins. At the start of resuscitation, animals in the nebulized HTS groups received the first dose of HTS; 2 mL of 7.5% HTS were delivered via a mixer at an airflow rate of 2 L/min for 15 mins. Animals were resuscitated by infusing two times the SB volume in normal saline (NS) over 30 mins, followed by 1/2 SB volume over 30 mins. Resuscitation was then completed using two times the SB volume in NS over 60 mins via the femoral vein. The rats received additional doses of nebulized HTS during the second and third postshock hours. A bronchoalveolar lavage was performed using 5 mL of saline, repeating the process two times (15 mL total) as the animal was euthanized via a pentobarbital overdose.
Lung Neutrophil Accumulation. At the end of the experiment, lung tissue was harvested, frozen, and stored at −80°C. It was weighed, and homogenized in 10 mL of 20 mmol/L potassium phosphate buffer, and centrifuged at 40,000g for 30 mins. The pellet was sonicated for 90 secs in 4 mL of 50 mmol/L potassium phosphate buffer containing 0.5 g/dL hexadecyltrimethyl ammonium bromide, incubated at 60°C and centrifuged. The supernatant (5 μL) was added to 145 μL of 50 mmol/L potassium phosphate buffer containing 0.167 mg/mL O-dianisidine with 0.0005% hydrogen peroxide; the absorbance at 460 nm was measured with a spectrophotometer (Molecular Devices Corp, Sunnyvale, CA) to determine myeloperoxidase activity (18, 19) .
Lung Vascular Permeability. Five milliliters of cold saline (NS) was injected into the trachea, aspirated a total of three times, and collected. The content of bronchoalveolar lavage fluid (BALF) collected was consistently > 12 mL. The BALF was then centrifuged at 400g at 4°C for 10 mins. Bronchoalveolar lavage protein content was determined by the bicinchoninic acid assay and absorbance read at 595 nm.
BALF Cytokines and MMPs. Due to mounting evidence that matrix MMPs are critical in the development of ALI (20) , we evaluated an array of MMPs and tissue inhibitors of matrix metalloproteinases (TIMPs) using a multiplexed enzyme-linked immunosorbent assay (RayBiotech, Norcross, GA). Cytokine-induced neutrophil chemoattractant-1 (CINC-1), the murine analog of IL-8, produced primarily by pulmonary epithelial cells and alveolar macrophages, was used as a marker of inflammation (21) . CINC-1 concentration in BALF was determined using a commercial immunoassay (Quantikine ELISA Kit; R&D Systems, Minneapolis, MN).
MMP-13 Inhibition. To test the effect of MMP-13 inhibition specifically, a separate group of Sprague-Dawley rats (n = 5, 350-400 g) were pretreated with intratracheal instillation of an MMP-13 inhibitor (100 µM CL-82198 in 100 µL NS) before the onset of trauma (laparotomy) and hemorrhagic shock (mean arterial pressure 30 mm Hg × 45 min). The animals were resuscitated with a combination of normal saline and heparinized SB. Each animal was given a lethal dose of pentobarbital at 3 hrs postinjury, at which time the BALF was collected for analysis using the colorimetric bicinchoninic acid protein assay.
Data Analysis. For the statistical analysis, data are reported as mean ± sem. Student's t test was used to determine statistical significance.
RESULTS
Lung Vascular Permeability. The primary end point of the study was ALI, measured by protein extravasation into the alveolar space 3 hrs after injury. Trauma/ hemorrhagic shock provoked marked lung permeability (1.56 ± 0.2 mg protein/mL BALF; n = 5), compared to sham (0.10 ± 0.03 mg protein/mL BALF; n = 5). This lung injury was attenuated with administration of aerosolized 7.5% saline (0.95 ± 0.3 mg protein/mL BALF; p = .018 Shock vs. Shock + HTS, n = 5) ( Fig. 1) .
Neutrophil Accumulation in the Lung. PMN accumulation, as measured by myeloperoxidase activity, was elevated following trauma/hemorrhagic shock compared to sham (7.77 ± 1.84 units/mg vs. 2.81 ± 1.84 units/mg, p = .009 Sham vs. Shock). Nebulized HTS decreased the neutrophil accumulation in the lung, although the effect was not significant Histology. Formalin-fixed lung sections stained with hematoxylin and eosin were evaluated by a pathologist in a blinded fashion. Lung sections show disruption of distal airspaces caused by trauma and hemorrhagic shock ( Fig. 3B ). Nebulized HTS administration protected the integrity of the basement membrane ( Fig. 3C ), giving it an appearance resembling normal rat lung parenchyma (Fig.  3A) . Additionally, MMP-13 was detectable in normal rat lung epithelium lining the alveoli, and following trauma/hemorrhagic shock in the injured lung there was prominent MMP-13 fluorescence in the epithelium lining the injured alveolus by epitope staining (Fig. 4) .
CINC-1 in BAL Fluid. Pulmonary cytokine activity was quantified in the BALF. CINC-1, the murine analog of human IL-8, was elevated substantially following trauma/hemorrhagic shock. CINC-1 accumulation in the BALF decreased by nearly 50% following nebulized HTS administration (CINC-1: 5999 ± 1267 pg/mL vs. 3342 ± 859 pg/mL, Shock vs. Shock + HTS groups, p = .03) ( Fig. 5 ).
Matrix Metalloproteinases. MMP-13, although present in the normal lung tissue, was virtually undetectable in normal BAL fluid (n = 5, value below the limit of detection <43.6 pg/mL), increasing dramatically following trauma/hemorrhagic shock to 1513 ± 337 pg/mL. Nebulized HTS inhibited MMP-13 accumulation in the BAL fluid to 230 ± 19 pg/mL, Shock vs. Shock + HTS, p = .009, n = 5 in both groups (Fig. 6 ). The level of MMP 8 produced by PMNs and epithelium was elevated but unchanged. TIMP-4 was detected, but not significantly altered by HTS. TIMP-1 levels were decreased 5.1fold by nebulized HTS (17.6 ± 9.9 pg/mL BALF vs. 2.4 ± 1.4 pg/mL, Shock vs. Shock + HTS groups, p = .0575, n = 5 in both groups), data are summarized in (Fig. 7) . It has been suggested that dysfunction of the constitutive inhibitors of MMPs (TIMPs) are the driving factor for acute lung inflammation in asthma exacerbation rather than increased activity of the MMPs themselves (22) . In rodents, MMP-13 performs the role of human MMP-1 (23) . We therefore measured TIMP-1, the inhibitor of rodent MMP-13 to explore this hypothesis, and found that, although nebulized HTS decreased TIMP-1 levels in BALF by 5-fold, the levels were inadequate for the production necessary for TIMP-1 to provide a 1:1 stoichiometric inhibition of MMP-13. Thus loss of TIMP-1 is unlikely to be a significant mechanism of nebulized HTS, compared to the massive increase in MMP13 induced by shock and ameliorated by HTS.
MMP-13 Inhibition. Recognizing that epithelial MMP-13 may be an important mediator of pulmonary inflammation via its collagenase and gelatinase activities, in a separate experiment, we treated the animals with an MMP-13 inhibitor. In these animals, hemorrhagic shock caused marked lung permeability, which was attenuated with MMP-13 inhibition. Pretreatment with an MMP-13 inhibitor was sufficient to attenuate postinjury ALI as reflected by BAL protein (1.42 ± 0.09 mg/mL vs. 0.77 ± 0.23 mg/mL protein in BALF, Shock vs. Shock + MMP-13 inhibitor, n = 5, p = .002) ( Fig. 8) . These data implicate MMP-13 and the epithelium in the development of ALI. Serum Sodium. To determine whether nebulized HTS was acting locally and not via systemic hypertonicity, serum sodium levels at baseline and at the end of resuscitation were measured and unchanged between the two groups (Shock group: 139 ± 4.5 mEq/L baseline vs. 143 ± 0.2 mEq/L at end of resuscitation; Shock + HTS group: baseline 140 ± 0.2 mEq/L vs. 145 ± 1 mEq/L at end of resuscitation. Serum sodium Baseline: Shock vs. Shock + HTS groups, p = .39, Serum sodium at end of resuscitation: Shock vs. Shock + HTS groups, p = .15). Osmolarity of the BAL fluid following nebulized HTS administration was measured using the Advanced Micro Osmometer 3000 (Advanced Instruments, Inc., Norwood, MA) and was found to be unchanged compared to the control group (Shock group 288 ± 0.54 mOsm/mL vs. HTS Shock group 311 ± 8.0 mOsm/mL, p = .11).
DISCUSSION
Our data indicate that nebulized HTS attenuates lung injury following experimental trauma/hemorrhagic shock. Nebulized HTS has already shown clinical benefit for patients with CF and neonatal bronchiolitis, and our study supports it as a novel treatment for ALI/ARDS.
We are merely proposing a novel method of delivery; the use of HTS in trauma is well established. HTS has optimal qualities for trauma resuscitation by reducing intracranial pressure via its higher osmotic load and attenuating the body's pro-inflammatory response to reduce the occurence of ARDS and multiple organ failure (24) . In the scenario of a growing body of in vitro, in vivo, and preclinical studies, in 2008 a large clinical trial comparing HTS with conventional NS resuscitation in the field showed that HTS increased early mortality and was no better than standard of care for overall mortality (25) . One of the proposed mechanisms for increased mortality in patients receiving HTS was a higher rate of early hemorrhage, because HTS impairs enzymatic clotting function when replacing 10% or more of the blood volume (26) .
Although hypertonicity acts systemically on the endothelium, nebulized HTS acts locally, delivering very small quantities of sodium to the systemic circulation (27) . In our model, 2 mL of 7.5% HTS was nebulized into a breathing mixer with high air-flow (2 L/min) for 15 mins. The assumption of a particle deposition of approximately 10% over the entire 15 min session suggests pulmonary addition of about 750µg or 13µmoles of NaCl and 10µL of H 2 O per session (28) . Therefore, it is unlikely that nebulized HTS exerted its activity at the endothelial-PMN interface. In our study, nebulized HTS exerted a minimal effect on neutrophil accumulation in the lung while attenuating accumulation of the chemokine CINC-1 in the BALF. These data suggest that the inhaled HTS is acting locally on the epithelium in the lung to modulate inflammation rather than mediating the interaction between the PMN and the vascular endothelium.
In the clinical setting, Reeves et al (29) , have also touted the anti-inflammatory effects of nebulized HTS in patients with CF. In their study, aerosolized HTS led to degradation of IL-8 and decreased neutrophil efficiency. Total IL-8 levels decreased by 33% in CF patients following treatment with nebulized HTS, which was comparable to observations in our study, in which nebulized HTS decreased CINC-1 levels (murine analog of IL-8) in the BALF by 44%. In CF patients, the data show a reduction in neutrophil chemotaxis as a result of chemokine degradation and disruption of IL-9, glycosaminoglycan complexes, suggesting that the nebulized HTS may be facilitating resolution of inflammation via a similar mechanism postinjury.
Additionally, our data show that hemorrhagic shock-induced lung permeability was attenuated with MMP-13 inhibition, further implicating the epithelium in the development of ALI. MMPs are a family of metalloendopeptidases, and collectively, are able to completely degrade the extracellular matrix. Although MMPs are not normally expressed in healthy tissues, they are integral in maintaining the extracellular matrix and tissue remodeling during repair processes (30) . MMP-13 is increased in Type II pneumocytes during chronic inflammation, and recent data have implicated MMP-13 in the development of sepsis-mediated ALI (17, 18) . Recognizing that epithelial MMP-13 may be an important mediator of pulmonary inflammation via its collagenase and gelatinase activities, we show that pretreatment with an MMP-13 inhibitor prior to trauma/hemorrhagic shock attenuates ALI.
Although we did not measure it directly, our study suggests that when the epithelial sodium channels are impaired during ALI/ARDS postshock nebulized HTS may augment alveolar fluid clearance in a similar way as it has been shown to do in CF. In addition to its anti-inflammatory effects, inhaled HTS may facilitate the resolution of alveolar edema by augmenting active ion transport across the pulmonary epithelium (31) . The ability of nebulized HTS to increase the airway surface volume and improve mucous clearance in CF patients has been the basis for giving this therapy (32) . In ARDS, the epithelial sodium channels become overwhelmed, and impaired alveolar fluid clearance leads to pulmonary edema formation (33) . The observation that inhaled HTS alters airway ion permeability may partly explain its recent success in treating bronchiolitis (34) .
We acknowledge that choosing a model that is relevant to the human disease is critical for successful translational research (35). Because no single animal model can fully reproduce the pathologic findings of human ALI/ARDS, our model focuses on inducing the pathologic "ALI triad" as described by Matute-Bello et al and Matute-Bello and Matthay (36, 37) . Over 45 yrs of clinical experience in caring for trauma patients form the basis for the clinically relevant model of early ALI used in this study. In fact, the first patient with ARDS successfully treated by Ashbaugh and Petty (38) was a 15-yr old trauma patient in hemorrhagic shock resulting from a motor vehicle crash.
To our knowledge, this study is the first to propose nebulized HTS as a therapy for ALI/ARDS. A phase II clinical trial to evaluate the role of nebulized HTS is currently underway in the surgical intensive care unit at Denver Health Medical Center, located 3 miles from the historic Colorado General Hospital, where Ashbaugh and Petty made their original contribution.
This study has several potential limitations. Neutrophil accumulation in lung tissue was decreased, although not significantly. This could be due to the small sample size or the early time course of the study may have led to the small absolute reduction in neutrophils in the lung tissue. Additionally, our model incorporates tissue injury (laparotomy) and hemorrhagic shock. We did not account for lung injury from direct trauma to the chest as can occur clinically, however, nebulized HTS may be beneficial for these patients as well, via enhanced clearance of edema fluid. Although we looked at TIMPs as endogenous inhibitors of MMPs, recent work has shown that nonspecific protease inhibitors (i.e., α-2 macroglobulin) may also have an important role in regulation of MMPs (39) . Additionally, the choice of resuscitation fluid alone can affect inflammation (40, 41) . Other studies, however, have shown that NS and lactated Ringer resuscitation fluids have equivalent effects on inflammatory markers, and that even large volume normal saline resuscitation has been shown to have an insignificant effect on oxygenation compared with lactated Ringer (42, 43) . Although NS may contribute to a hyperchloremic metabolic acidosis, the calcium content in lactated Ringer can impair coagulation. Therefore, in our model of trauma and hemorrhagic shock, we prefer to use normal saline.
In summary, nebulized HTS reduces epithelial cytokine and MMP-13 accumulation in BAL fluid, thereby attenuating ALI and preserving basement membrane integrity in the distal airways without altering PMN accumulation in the lung. These data further support the role of epithelial damage in the pathogenesis of ALI. These results suggest that nebulized HTS attenuates ALI by suppressing epithelial inflammation, supporting further research regarding its use as a novel strategy to treat ALI/ARDS. 
